Ashton Thomas Private Wealth LLC increased its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 5,072.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,127 shares of the biotechnology company's stock after purchasing an additional 107,998 shares during the period. Axon Enterprise makes up 0.9% of Ashton Thomas Private Wealth LLC's investment portfolio, making the stock its 11th largest holding. Ashton Thomas Private Wealth LLC owned about 0.14% of Axon Enterprise worth $46,531,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in AXON. MassMutual Private Wealth & Trust FSB lifted its holdings in Axon Enterprise by 122,993.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 461,601 shares of the biotechnology company's stock valued at $195,036,000 after purchasing an additional 461,226 shares in the last quarter. B. Metzler seel. Sohn & Co. AG purchased a new position in Axon Enterprise in the 2nd quarter worth about $3,854,000. Arrowstreet Capital Limited Partnership acquired a new position in Axon Enterprise during the first quarter valued at approximately $15,067,000. Brown Lisle Cummings Inc. raised its stake in shares of Axon Enterprise by 97,231.4% in the second quarter. Brown Lisle Cummings Inc. now owns 34,066 shares of the biotechnology company's stock valued at $19,098,000 after acquiring an additional 34,031 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Axon Enterprise by 40.7% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company's stock worth $6,406,000 after purchasing an additional 4,360 shares in the last quarter. 79.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have weighed in on AXON. Raymond James Financial set a $675.00 target price on shares of Axon Enterprise in a research note on Thursday, October 15th. Northcoast Research lifted their price objective on shares of Axon Enterprise from $650.00 to $680.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Piper Sandler reiterated an "overweight" rating and issued a $540.00 price objective (down from $561.00) on shares of Axon Enterprise in a research report on Friday. TD Cowen cut their price target on Axon Enterprise from $825.00 to $800.00 and set a "buy" rating for the company in a research note on Monday, October 26th. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "hold" rating and set a $390.00 price objective for the company. in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $631.35.
Check Out Our Latest Analysis on AXON
Axon Enterprise Stock Performance
Shares of NASDAQ AXON opened at $313.00 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. The stock has a market cap of $25.43 billion, a price-to-earnings ratio of 100.32, a P/E/G ratio of 8.09 and a beta of 1.48. The stock's 50-day moving average is $441.53 and its 200 day moving average is $475.20. Axon Enterprise, Inc has a 1-year low of $307.00 and a 1-year high of $665.07.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The business had revenue of $908.55 million for the quarter, compared to analysts' expectations of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The company's revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.17 EPS. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 2.10 EPS for the current fiscal year.
More Axon Enterprise News
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
- Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
- Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
- Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
- Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement
Insider Activity at Axon Enterprise
In related news, insider Isaiah Fields sold 1,017 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $480.45, for a total value of $488,617.65. Following the completion of the transaction, the insider owned 56,264 shares of the company's stock, valued at $27,032,038.80. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total value of $5,089,900.00. Following the completion of the transaction, the chief executive officer owned 3,118,012 shares of the company's stock, valued at $1,587,036,927.88. The trade was a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,397 shares of company stock worth $21,234,034 over the last three months. 4.20% of the stock is currently owned by company insiders.
Axon Enterprise Profile
(
Free Report)
Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.
The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.
Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
